Progranulin deficiency promotes neuroinflammation and neuron loss following toxin-induced injury

Lauren Herl Martens,1 Jiasheng Zhang,2,3 Sami J. Barmada,4,5 Ping Zhou,1 Sherry Kamiya,2,3 Binggui Sun,4 Sang-Won Min,4 Li Gan,4,6 Steven Finkbeiner,4,5,6,7,8 Eric J. Huang,2,3,6 and Robert V. Farese Jr.1,6,9

1Gladstone Institute of Cardiovascular Disease, San Francisco, California, USA. 2Department of Pathology, UCSF, San Francisco, California, USA. 3Pathology Service 113B, VA Medical Center, San Francisco, California, USA. 4Gladstone Institute of Neurodegenerative Disease, San Francisco, California, USA. 5Department of Neurology, 6Consortium for Frontotemporal Dementia Research, 7Department of Physiology, 8Taube-Koret Center for Huntington’s Disease Research and Hellman Family Foundation Program in Alzheimer’s Disease Research, and 9Departments of Medicine, Biochemistry and Biophysics, UCSF, San Francisco, California, USA.

Progranulin (PGRN) is a widely expressed secreted protein that is linked to inflammation. In humans, PGRN haploinsufficiency is a major inherited cause of frontotemporal dementia (FTD), but how PGRN deficiency causes neurodegeneration is unknown. Here we show that loss of PGRN results in increased neuron loss in response to injury in the CNS. When exposed acutely to 1-methyl-4-(2′-methylphenyl)-1,2,3,6-tetrahydropyridine (MPTP), mice lacking PGRN (Grn–/–) showed more neuron loss and increased microgliosis compared with wild-type mice. The exacerbated neuron loss was due not to selective vulnerability of Grn–/– neurons to MPTP, but rather to an increased microglial inflammatory response. Consistent with this, conditional mutants lacking PGRN in microglia exhibited MPTP-induced phenotypes similar to Grn–/– mice. Selective depletion of PGRN from microglia in mixed cortical cultures resulted in increased death of wild-type neurons in the absence of injury. Furthermore, Grn–/– microglia treated with LPS/IFN-γ exhibited an amplified inflammatory response, and conditioned media from these microglia promoted death of cultured neurons. Our results indicate that PGRN deficiency leads to dysregulated microglial activation and thereby contributes to increased neuron loss with injury. These findings suggest that PGRN deficiency may cause increased neuron loss in other forms of CNS injury accompanied by neuroinflammation.

Introduction
Progranulin (PGRN) is an approximately 70-kDa secreted protein involved in cellular processes such as wound healing and inflammation (1, 2). PGRN has been implicated as a regulator of TNF-α-mediated inflammation (3) and also has growth factor properties, with roles in cellular proliferation and survival (1). PGRN can be processed to granulin (GRN) peptides (4), which may have different functions (5). PGRN is expressed widely in tissues and circulates in the blood and cerebrospinal fluid (6, 7).

Mutations in GRN are causally linked to frontotemporal dementia (FTD) (8–10). Various types of mutations have been found that result in GRN haploinsufficiency and cause a >50% reduction in circulating PGRN (11). PGRN is expressed in neurons and microglia (7); the contribution of PGRN deficiency in these cell types to FTD is unknown. Intracellular aggregates of TDP-43 are found in neurons of subjects with PGRN-deficient FTD, and TDP-43 may contribute to neuron loss (12). However, microglial PGRN expression is increased in Alzheimer’s disease and amyotrophic lateral sclerosis (13, 14), suggesting that it may play a more general role in neuroinflammation and neurodegeneration.

We and several groups have used murine models to examine the effects of PGRN deficiency in the CNS. Neurons of PGRN-knockout (Grn–/–) mice develop ubiquitin-positive aggregates and phosphorylated TDP-43, similar to FTD patients with GRN mutations (15–20). Neurons from Grn–/– mice exhibit reduced survival in culture (21). In addition, PGRN deficiency results in gliosis in the CNS of aged mice (L.H. Martens, unpublished observations, and refs. 15–20). PGRN expression is also upregulated following axotomy of the sciatic nerve in the peripheral nervous system (22). These latter observations suggest that PGRN may modulate inflammation in the CNS, consistent with studies showing that PGRN deficiency predisposes macrophages to increased inflammation (15).

Here we tested the hypothesis that PGRN attenuates the inflammatory response to CNS injury. We used the acute injury model of treatment with 1-methyl-4-(2′-methylphenyl)-1,2,3,6-tetrahydropyridine (MPTP), a neurotoxin that targets the dopaminergic neurons of the substantia nigra pars compacta (SNpc). Although MPTP injury is commonly used as a Parkinson’s disease model, it provides a reproducible CNS injury with consistent neuron loss and reactive gliosis (23). We examined the effects of MPTP on neuron survival and microglial activation in PGRN-deficient mice and utilized primary cultures of neurons and microglia to investigate mechanisms.

Results and Discussion
To investigate PGRN expression and function in the CNS, we generated a conditional Grn allele and, subsequently, Grn–/– mice by crossing Grnβ/β mice with β-actin–Cre mice (ref. 24 and Supplemental Figure 1, A–C; supplemental material available online with this article; doi:10.1172/JCI63113DS1). In adult mouse brains, PGRN was expressed primarily in neurons and in resting and reactive microglia (Supplemental Figure 1D and Supplemental Figure 2, A–C).
Because PGRN is expressed in activated microglia (22) and antagonizes inflammation (3), we hypothesized that PGRN attenuates the inflammatory response to CNS injury. To test this hypothesis, we chose a model in which injury was induced by MPTP, which, at high doses, acutely causes inflammation and death of SNpc dopaminergic neurons (23). Neuron toxicity is in part due to conversion of MPTP to MPP⁺, which is taken up by dopaminergic neurons and blocks electron transport (23). Additionally, microglia are activated and secrete cytotoxic, proinflammatory cytokines, such as TNF-α (23, 25).

Three-month-old Grn⁺/+, Grn⁻/⁻, and Grn⁻/- mice were treated with MPTP or vehicle (PBS) for 2 days (Figure 1A). In vehicle-treated mice of any genotype, the numbers of dopaminergic (tyrosine hydroxylase [TH]–positive) neurons in SNpc were similar, indicating that PGRN deficiency did not affect their survival (Figure 1, A and B). As expected, MPTP treatment induced approximately 37% loss of dopaminergic neurons in the SNpc of Grn⁺/+ mice (Figure 1B). More strikingly, dopaminergic neurons were reduced by approximately 66% in Grn⁻/- mice, and by approximately 50% in Grn⁻/- mice. Quantification of Nissl-positive neurons in SNpc showed similar deficits in Grn⁺/+ and Grn⁻/- mice following MPTP treatment (Supplemental Figure 3, A and B). While there were no detectable differences in the numbers of resting microglia, MPTP treatment increased activated microglia in SNpc by 2.84-fold in Grn⁻/- mice and 1.33-fold in Grn⁺/- mice, compared with Grn⁺/+ mice (Figure 1, B and D). Most Grn⁻/- microglia were highly ramified and large, indicative of activated microglia (Figure 1D and ref. 25).

To further investigate the contribution of PGRN expression in microglia in the MPTP-induced injury model, we crossed Grnfl/fl mice with Cd11b-Cre mice (26) to generate mice with PGRN deficiency in microglia (Cd11b-Cre+;Grnfl/fl). PGRN mRNA levels and secretion were decreased in primary microglia cultured from Cd11b-Cre+;Grnfl/fl mice by approximately 54% and 42%, respectively, but not cortical neurons (Supplemental Figure 4, A and B). Consistent with the results with Grn⁻/- mice, Cd11b-Cre+;Grnfl/fl mice showed a similar reduction in dopaminergic neurons (Figure 1C and Supplemental Figure 4C) and increased microgliosis after MPTP treatment (Figure 1C and Supplemental Figure 4D). Together, these results supported that PGRN deficiency in microglia is sufficient to cause increased inflammation and reduced neuron survival following CNS injury.
To further investigate the effects of PGRN deficiency in microglia, we utilized primary cell culture models. Both primary neurons and microglia expressed *Grn* mRNA, with much higher levels in microglia (Figure 2A), which are activated during culturing (27). We examined whether PGRN deficiency alters neuron survival in the absence of glia by testing the susceptibility of *Grn*+/+ and *Grn*–/– dopaminergic neurons (E13.5) to various doses of MPP+ for 3 days. Neuron death occurred in a dose-dependent manner following MPP+ exposure, but there were no differences in the numbers of surviving wild-type or PGRN-deficient TH- and TUJ1-positive neurons (Figure 2B).

We next asked whether PGRN deficiency in microglia had effects on neuron survival. We isolated mixed cortical cultures—containing neurons, microglia, and astrocytes—from (P0) *Grn*fl/fl mice and selectively depleted *Grn* in microglia by infecting with Iba1-Cre lentivirus (Iba1-Cre). Depletion of PGRN from microglia reduced PGRN in the medium by approximately 70% (Figure 2, C and D) and reduced the survival of MAP2-positive neurons by >50% compared with controls (Figure 2E). There were no apparent changes in the numbers of microglia or astrocytes (data not shown). Thus, PGRN deficiency in microglia is sufficient to increase death of wild-type neurons in primary cultures.

We hypothesized that the increased neuron death observed when microglia are deficient in PGRN may be attributable to alterations in secreted factors. To test this hypothesis, we collected conditioned media from *Grn*+/+ and *Grn*–/– microglia treated with either PBS or LPS/IFN-γ for 24 hours and then transferred the media to wild-type cortical neurons to assess survival. The cumulative risk of death for each treatment was determined using Kaplan-Meier survival analysis, which assessed the probability of neuron cell death over time (28, 29). There were no differences in survival of neurons exposed to conditioned media of PBS-treated *Grn*+/+ or *Grn*–/– microglia (Figure 2F). In contrast, exposure of *Grn*+/+ and *Grn*–/– microglia to LPS/IFN-γ caused significantly more neuron cell death than PBS, and this effect was accentuated with conditioned media from activated *Grn*–/– microglia. These results indicate that activated PGRN-deficient microglia likely secrete factors that promote the death of wild-type neurons.

To investigate this phenomenon further, we examined the inflammatory response in primary microglia following 24 hours of treatment with LPS/IFN-γ. Similar to findings for PGRN-deficient macrophages (3, 15), *Grn*–/– microglia expressed and secreted increased amounts of the proinflammatory cytokines *Tnfa*, *Il1b*, and *Il6* compared with controls (Figure 3, A and B). *Grn*–/– microglia also expressed less anti-inflammatory *Il10* mRNA after
24 hours (Figure 3A), although increased amounts of IL-10 were secreted into the media (Figure 3B), reflecting differences in the regulation of mRNA versus secreted protein. The increased IL-10 secretion was apparently insufficient to dampen the increased inflammatory state of Grn−/− microglia. These data indicate that Grn−/− microglia are prone to a hyperactive proinflammatory state upon activation, and this hyperactivation likely contributes to the death of neurons. These data also suggest that a function of PGRN is to dampen the activation state of microglia upon stimulation. Supporting this, lentivirus-mediated overexpression of murine PGRN (MuGrn) did not attenuate neuron death in our system (Supplemental Figure 6). We are unable to distinguish whether this was due to inadequate TNF-α blockade or whether other factors — such as increased cytokines or excitatory factors, or decreased trophic factors — are responsible for the increased neuron death.

Our findings suggest that PGRN deficiency may predispose microglia to hyperactivation and neuron death in FTD. Indeed, microglial activation is found in humans with FTD (33) and in murine models of PGRN deficiency (15–20). However, our findings do not exclude that PGRN deficiency in neurons may also be an important contributing factor. Several studies have demonstrated that PGRN has important neurotrophic properties (21, 34), and indeed, we found small reductions in the survival of Grn−/− cortical neurons cultured in nutrient-rich (B27) or nutrient-depleted (N2) media (Supplemental Table 1). Nevertheless, our results reveal a role for PGRN in attenuating neuroinflammation and suggest that this mechanism contributes to neurodegeneration in PGRN-deficient FTD. Further, PGRN may attenuate inflammation and neuron death in other forms of neurodegeneration or CNS injury. Therapies aimed at raising PGRN levels (35, 36) in the CNS therefore may prove useful as therapies for FTD and other forms of CNS injury.

**Methods**

Experimental procedures are described in detail in Supplemental Methods.

**Generation of PGRN-deficient mice.** A targeting vector was generated with loxP sites flanking the Grn coding sequence. GrnloxPloxP mice were bred with mice expressing Cre recombinase under β-actin (24) or Cd11b (26) promoters.

**Acute MPTP treatment.** Three-month-old mice were treated with 4 i.p. injections of MPTP per day for 2 days (4 μg/g body weight) (Sigma-Aldrich) or PBS. Stereological counting was used to quantify dopamine neurons and microglia in the SNpc.

**Primary cultures.** Ventral midbrain, cortical neuron, mixed cortical, and microglial cultures were prepared from E13.5 or E16–18 embryos and P0 or P2–P4 pups.

**Neuron survival assays.** Pure cortical cultures were transfected with EGFP, microglial conditioned media was added, and cells were imaged every 24 hours using an automated microscopy system (28) to assess neuron death.

**Cytokine analysis.** Primary microglia were stimulated with PBS or 100 ng/ml LPS (Sigma-Aldrich) and 100 U/ml IFN (Sigma-Aldrich). Secreted cytokine levels were measured using the Mouse Pro-inflammatory 7-plex cytokine ELISA kit (Meso Scale Discovery).
We thank L. Mitic and T. Nguyen for helpful discussions, L. Elia for murine PGRN ELISA assistance, L. Martin for etanercept, and G. Diaz-Ramirez for mouse husbandry. This work was supported by grants from the NIH (PS0 AG023501 [to R.V. Fares Jr.], GMO 10909 [to R.V. Fares Jr.], F31 AG034793 [to L.H. Martens], P01 AG022074 [to S. Finkbeiner], K26 OD010927 [to E.J. Huang], K08 NS072233 [SBJ]), VA Merit Award BX001108 (to E.J. Huang), the Consortium for Frontotemporal Dementia Research (to R.V. Fares Jr.), the ALS Association (to S. Finkbeiner), and the Gladstone Institutes. The Gladstone Institutes received support from a National Center for Research Resources grant RR18928.

Received for publication January 30, 2012, and accepted in revised form August 17, 2012.

Address correspondence to: Eric J. Huang, Department of Pathology, University of California San Francisco, 513 Parnassus Avenue, San Francisco, California 94143-0502, USA. Phone: 415.476.8525; Fax: 415.514.0878; E-mail: eric.huang2@ucsf.edu. Or to: Robert V. Fares Jr., Gladstone Institutes, 1650 Owens Street, San Francisco, California 94158, USA. Phone: 415.734.2718; Fax: 415.355.0960; E-mail: bfares@gladstone.ucsf.edu.